Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen Utikal
Selma Ugurel

Showing results (321-330 of 490) with videos related to

Pageof 49
Sort By:
Frontiers in Oncology|August 30, 2021
Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition - Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 ImmunohistochemistryJan-Malte Placke, Josefine Rawitzer, Henning Reis, et al.
The Journal of Investigative Dermatology|February 25, 2006
Absence of classical MAP kinase pathway signalling in Merkel cell carcinomaRoland Houben, Barbara Michel, Claudia S Vetter-Kauczok, et al.
Journal for Immunotherapy of Cancer|March 18, 2022
STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing miceRebekka Bitsch, Annina Kurzay, Feyza Özbay Kurt, et al.
Cancers|December 17, 2020
HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in MelanomaLaura Hüser, Marianthi-Maria Kokkaleniou, Karol Granados, et al.
Scientific Reports|July 20, 2021
TRPV1 activation and internalization is part of the LPS-induced inflammation in human iPSC-derived cardiomyocytesKatherine Sattler, Ibrahim El-Battrawy, Lukas Cyganek, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 3, 2021
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell CarcinomaJustin Ferdinandus, Wolfgang P Fendler, Katharina Lueckerath, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunityRalf Gutzmer, Anika Koop, Friedegund Meier, et al.
European Journal of Medicinal Chemistry|May 30, 2023
Development of a next-generation endogenous OCT4 inducer and its anti-aging effect in vivoHan Kang, Sebastian Hasselbeck, Katerina Taškova, et al.
Scientific Reports|September 1, 2025
Distinct liver sections exhibit sex-specific gene expression patterns in Lewis ratsLuisa Sophie Rajcsanyi, Simge Oral, Julia Borgardt, et al.
Iscience|January 28, 2019
Imidazopyridines as Potent KDM5 Demethylase Inhibitors Promoting Reprogramming Efficiency of Human iPSCsYasamin Dabiri, Rodrigo A Gama-Brambila, Katerina Taškova, et al.
Pageof 49

Showing results (321-330 of 490) with videos related to

Sort By:
Pageof 49
Frontiers in Oncology|August 30, 2021
Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition - Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 ImmunohistochemistryJan-Malte Placke, Josefine Rawitzer, Henning Reis, et al.
The Journal of Investigative Dermatology|February 25, 2006
Absence of classical MAP kinase pathway signalling in Merkel cell carcinomaRoland Houben, Barbara Michel, Claudia S Vetter-Kauczok, et al.
Journal for Immunotherapy of Cancer|March 18, 2022
STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing miceRebekka Bitsch, Annina Kurzay, Feyza Özbay Kurt, et al.
Cancers|December 17, 2020
HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in MelanomaLaura Hüser, Marianthi-Maria Kokkaleniou, Karol Granados, et al.
Scientific Reports|July 20, 2021
TRPV1 activation and internalization is part of the LPS-induced inflammation in human iPSC-derived cardiomyocytesKatherine Sattler, Ibrahim El-Battrawy, Lukas Cyganek, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 3, 2021
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell CarcinomaJustin Ferdinandus, Wolfgang P Fendler, Katharina Lueckerath, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunityRalf Gutzmer, Anika Koop, Friedegund Meier, et al.
European Journal of Medicinal Chemistry|May 30, 2023
Development of a next-generation endogenous OCT4 inducer and its anti-aging effect in vivoHan Kang, Sebastian Hasselbeck, Katerina Taškova, et al.
Scientific Reports|September 1, 2025
Distinct liver sections exhibit sex-specific gene expression patterns in Lewis ratsLuisa Sophie Rajcsanyi, Simge Oral, Julia Borgardt, et al.
Iscience|January 28, 2019
Imidazopyridines as Potent KDM5 Demethylase Inhibitors Promoting Reprogramming Efficiency of Human iPSCsYasamin Dabiri, Rodrigo A Gama-Brambila, Katerina Taškova, et al.
Pageof 49